Scarica l'app Stockscreener
3.824
0.13%
0.004
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
SAB Biotherapeutics (SABS) CMO has common shares withheld for taxes - Stock Titan
SAB Biotherapeutics - Global Legal Chronicle
[SCHEDULE 13D/A] SAB B... - Stock Titan
SAB Biotherapeutics Completes $85 Million Public Offering - Global Legal Chronicle
SAB Biotherapeutics closes $85 million public offering - The Pharma Letter
SAB Biotherapeutics (SABS) to Release Earnings on Friday - MarketBeat
SAB Biotherapeutics announces public stock offering; shares down - MSN
SAB Biotherapeutics Closes $85 Million Securities Offering - marketscreener.com
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Weekly Voice
SAB BIO raises $85 million to fund diabetes drug trials - Stock Titan
SAB Biotherapeutics (SABS) raises $69.7M net to advance SAB‑142 clinical program - Stock Titan
SAB Biotherapeutics Launches Major Equity Financing Offering - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) to raise $85M for SAB-142 trials - Stock Titan
SAB Biotherapeutics Prices Underwritten Equity Offering; About $69.7 Million Net Proceeds Expected - TradingView
Stock Recap: Is SAB Biotherapeutics Inc being accumulated by smart money2026 Market Outlook & Low Volatility Stock Recommendations - baoquankhu1.vn
Guggenheim initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com - Investing.com South Africa
SAB Biotherapeutics prices $85M stock offering at $3.85/share - Investing.com
Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share - marketscreener.com
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
SAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 Million - Quiver Quantitative
SAB BIO plans $85M funding push for experimental type 1 diabetes treatment - Stock Titan
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Benzinga
SAB Biotherapeutics (SABS) to offer common stock and pre-funded warrants - Stock Titan
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech SAB BIO plans stock sale to fund Type 1 diabetes trials - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update - MarketBeat
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Cut to “Strong Sell” at Zacks Research - Defense World
SAB Biotherapeutics reports early C-peptide signals in phase 1 trial - Investing.com Nigeria
SAB Biotherapeutics (NASDAQ:SABS) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
SAB Biotherapeutics (NASDAQ:SABS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Chardan Capital Raises SAB Biotherapeutics Price Target to $14 - National Today
Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00 - MarketBeat
H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution - Investing.com
SAB Biotherapeutics (NASDAQ:SABS) Given New $7.00 Price Target at HC Wainwright - Defense World
SAB Biotherapeutics Announces Positive Phase 1 Results for SAB-142 Showing C-Peptide Preservation in Adult Type 1 Diabetes Patients - Minichart
SAB Biotherapeutics, Inc. 2024 Annual Report: Business Overview, Pipeline, and Strategic Outlook - Minichart
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - National Today
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright - MarketBeat
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data - TipRanks
SAB Bio (SAB Biotherapeutics, Inc.) recently released further data from a Phase I clinical trial of its candidate drug SAB-142 in adult patients diagnosed with autoimmune type 1 diabetes. - Bitget
SAB Bio reports Phase 1 SAB-142 data showing C-peptide preservation signals in adult T1D cohort - TradingView
Phase 1 SAB-142 data from SAB BIO (Nasdaq: SABS) highlight early T1D signal - Stock Titan
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - Investing News Network
SAB BIO backs diabetes therapy with $175M and 2027 trial goal - Stock Titan
SAB Biotherapeutics 10-K: Revenue $0, Net income $13.27M - TradingView
SAB Biotherapeutics (SABS) boosts cash with $175M raise and 2025 warrant gain - Stock Titan
How rising interest rates impact SAB Biotherapeutics Inc. stockPortfolio Update Report & Consistent Profit Alerts - Naître et grandir
Aug Mood: Can SAB Biotherapeutics Inc ride the EV wavePortfolio Growth Summary & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Breakout Watch: Is SAB Biotherapeutics Inc a turnaround story2025 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Published on: 2026-03-07 05:05:40 - baoquankhu1.vn
Nasdaq Moves: Is SAB Biotherapeutics Inc a cyclical or defensive stockRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
SABS SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SABS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):